Tags

Type your tag names separated by a space and hit enter

An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.
Int Immunopharmacol. 2021 Jul; 96:107763.II

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the rapidly spreading pandemic COVID-19 in the world. As an effective therapeutic strategy is not introduced yet and the rapid genetic variations in the virus, there is an emerging necessity to design, evaluate and apply effective new vaccines. An acceptable vaccine must elicit both humoral and cellular immune responses, must have the least side effects and the storage and transport systems should be available and affordable for all countries. These vaccines can be classified into different types: inactivated vaccines, live-attenuated virus vaccines, subunit vaccines, virus-like particles (VLPs), nucleic acid-based vaccines (DNA and RNA) and recombinant vector-based vaccines (replicating and non-replicating viral vector). According to the latest update of the WHO report on April 2nd, 2021, at least 85 vaccine candidates were being studied in clinical trial phases and 184 candidate vaccines were being evaluated in pre-clinical stages. In addition, studies have shown that other vaccines, including the Bacillus Calmette-Guérin (BCG) vaccine and the Plant-derived vaccine, may play a role in controlling pandemic COVID-19. Herein, we reviewed the different types of COVID-19 candidate vaccines that are currently being evaluated in preclinical and clinical trial phases along with advantages, disadvantages or adverse reactions, if any.

Links

PMC Free PDF

Authors+Show Affiliations

Motamedi H
Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Ari MM
Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Dashtbin S
Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Fathollahi M
Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Hossainpour H
Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Alvandi A
Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran; Medical Technology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Moradi J
Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Abiri R
Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran; Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. Electronic address: rabiri@kums.ac.ir.

MeSH

AdolescentAdultAgedAged, 80 and overAnimalsBCG VaccineCOVID-19COVID-19 VaccinesDrug Evaluation, PreclinicalFemaleHumansMaleMeta-Analysis as TopicMiddle AgedSARS-CoV-2Vaccines, DNAVaccines, InactivatedVaccines, SubunitVaccines, Virus-Like ParticleViral Vaccines

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

34162141

Citation

Motamedi, Hamid, et al. "An Update Review of Globally Reported SARS-CoV-2 Vaccines in Preclinical and Clinical Stages." International Immunopharmacology, vol. 96, 2021, p. 107763.
Motamedi H, Ari MM, Dashtbin S, et al. An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. Int Immunopharmacol. 2021;96:107763.
Motamedi, H., Ari, M. M., Dashtbin, S., Fathollahi, M., Hossainpour, H., Alvandi, A., Moradi, J., & Abiri, R. (2021). An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. International Immunopharmacology, 96, 107763. https://doi.org/10.1016/j.intimp.2021.107763
Motamedi H, et al. An Update Review of Globally Reported SARS-CoV-2 Vaccines in Preclinical and Clinical Stages. Int Immunopharmacol. 2021;96:107763. PubMed PMID: 34162141.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. AU - Motamedi,Hamid, AU - Ari,Marzie Mahdizade, AU - Dashtbin,Shirin, AU - Fathollahi,Matin, AU - Hossainpour,Hadi, AU - Alvandi,Amirhoushang, AU - Moradi,Jale, AU - Abiri,Ramin, Y1 - 2021/05/06/ PY - 2021/02/26/received PY - 2021/04/21/revised PY - 2021/05/04/accepted PY - 2021/6/24/entrez PY - 2021/6/25/pubmed PY - 2021/7/8/medline KW - COVID-19 KW - SARS-CoV-2 KW - Vaccines SP - 107763 EP - 107763 JF - International immunopharmacology JO - Int Immunopharmacol VL - 96 N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the rapidly spreading pandemic COVID-19 in the world. As an effective therapeutic strategy is not introduced yet and the rapid genetic variations in the virus, there is an emerging necessity to design, evaluate and apply effective new vaccines. An acceptable vaccine must elicit both humoral and cellular immune responses, must have the least side effects and the storage and transport systems should be available and affordable for all countries. These vaccines can be classified into different types: inactivated vaccines, live-attenuated virus vaccines, subunit vaccines, virus-like particles (VLPs), nucleic acid-based vaccines (DNA and RNA) and recombinant vector-based vaccines (replicating and non-replicating viral vector). According to the latest update of the WHO report on April 2nd, 2021, at least 85 vaccine candidates were being studied in clinical trial phases and 184 candidate vaccines were being evaluated in pre-clinical stages. In addition, studies have shown that other vaccines, including the Bacillus Calmette-Guérin (BCG) vaccine and the Plant-derived vaccine, may play a role in controlling pandemic COVID-19. Herein, we reviewed the different types of COVID-19 candidate vaccines that are currently being evaluated in preclinical and clinical trial phases along with advantages, disadvantages or adverse reactions, if any. SN - 1878-1705 UR - https://www.unboundmedicine.com/medline/citation/34162141/An_update_review_of_globally_reported_SARS_CoV_2_vaccines_in_preclinical_and_clinical_stages_ DB - PRIME DP - Unbound Medicine ER -